3SBio purchases entire collateral interest in Zhejiang Wansheng 3SBio Inc., , a leading China-based biotechnology company centered on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the complete equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a restricted liability company incorporated in the PRC for an aggregate consideration of RMB 528 million cost . 3SBio's proven capabilities in biologicals, combined with Zhejiang Wansheng's expertise in little molecule manufacturing, will provide the enlarged group with a flexible system for addressing the unmet medical needs of patients and their healthcare experts.
The laboratory is normally 3M Medication Delivery Systems’ first agreement research and development service in the Asia Pacific area focused on pharmaceutical product development. The country’s infrastructure helps it be an ideal hub for 3M’s Asia Pacific customers and Singapore’s scientific talent pool adds to the site’s appeal. The Singapore lab shall develop items in both inhalation and transdermal drug delivery groups, bringing 3M’s innovative inhalers and patches to pharmaceutical clients and individuals in the Asia Pacific area. Related StoriesInnovation in anaesthesia: an interview with Matti Lehtonen, GE HealthcareExpanded use for IntelliCap with additional CE Tag for aspiration of fluidsLiposomal sizing and the Coulter theory: an interview with Professor Melvin E.